Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > COMMENTARY
COMMENTARY
- Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
- Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
- With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
- Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
- MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
- Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
- Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
- As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
- MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
- Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
- “Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
- Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
- Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
- Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
- Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
- Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
- Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
- Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
- Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…